MX2018008707A - Metodos y composiciones para su uso en la prevencion, tratamiento y/o alivio del cancer. - Google Patents

Metodos y composiciones para su uso en la prevencion, tratamiento y/o alivio del cancer.

Info

Publication number
MX2018008707A
MX2018008707A MX2018008707A MX2018008707A MX2018008707A MX 2018008707 A MX2018008707 A MX 2018008707A MX 2018008707 A MX2018008707 A MX 2018008707A MX 2018008707 A MX2018008707 A MX 2018008707A MX 2018008707 A MX2018008707 A MX 2018008707A
Authority
MX
Mexico
Prior art keywords
serum
products
cancer
cadmium
concentration
Prior art date
Application number
MX2018008707A
Other languages
English (en)
Inventor
J Sirén Matti
Original Assignee
Siren Matti J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siren Matti J filed Critical Siren Matti J
Publication of MX2018008707A publication Critical patent/MX2018008707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La relación de los metales zinc y cadmio es de gran importancia para la proliferación y diferenciación libre de errores de las células. La comprensión del papel del cadmio en la etiología del cáncer ofrece la posibilidad de ganar en una mejor compresión del cáncer, así como también las posibilidades de prevenir, tratar y/o aliviar el cáncer. La concentración de Zn(II) en el suero fetal, en el suero humano de sangre del cordón umbilical o de donantes sanos, y en el suero aviar que incluye huevos intactos y productos de huevo, tiene importancia para la fiabilidad y repetibilidad del método de cultivo de células y tejidos que usa dicho suero, o productos que contienen suero, o huevos. En la presente descripción se describe una etapa del método en la fabricación de productos séricos, en particular productos séricos destinados para su uso en el cultivo in vitro de células o tejidos de mamíferos, en donde se determina la concentración de Zn(II), y se ajusta preferentemente a un intervalo deseado. Además, se describen productos diferentes que consisten en o que contienen suero o fracciones de suero.
MX2018008707A 2016-01-19 2017-01-19 Metodos y composiciones para su uso en la prevencion, tratamiento y/o alivio del cancer. MX2018008707A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650058 2016-01-19
PCT/EP2017/051091 WO2017125498A1 (en) 2016-01-19 2017-01-19 Methods and compositions for use in the prevention, treatment and/or alleviation of cancer

Publications (1)

Publication Number Publication Date
MX2018008707A true MX2018008707A (es) 2019-03-06

Family

ID=58044008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008707A MX2018008707A (es) 2016-01-19 2017-01-19 Metodos y composiciones para su uso en la prevencion, tratamiento y/o alivio del cancer.

Country Status (9)

Country Link
US (2) US10463695B2 (es)
EP (1) EP3405202A1 (es)
JP (1) JP2019505590A (es)
CN (1) CN108472316A (es)
AU (1) AU2017210247A1 (es)
BR (1) BR112018014596A2 (es)
CA (1) CA3015007A1 (es)
MX (1) MX2018008707A (es)
WO (1) WO2017125498A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219872A1 (en) 2021-05-21 2022-11-24 Kari SARVANTO Compounds inhibiting the synergistic carsinogenic effect of heavy metals in the presence of other carcinogens for use in the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
DK3677271T3 (da) * 2013-03-13 2023-05-22 Univ Miami Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider

Also Published As

Publication number Publication date
BR112018014596A2 (pt) 2018-12-11
US20200016197A1 (en) 2020-01-16
JP2019505590A (ja) 2019-02-28
EP3405202A1 (en) 2018-11-28
AU2017210247A1 (en) 2018-09-06
WO2017125498A1 (en) 2017-07-27
US20170202881A1 (en) 2017-07-20
US10463695B2 (en) 2019-11-05
CA3015007A1 (en) 2017-07-27
CN108472316A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
Galipeau The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
Zhang et al. Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches
MX2019010958A (es) Metodos de tratamiento de tumores.
MX2018010508A (es) Preparaciones mejoradas de celulas progenitoras hepaticas adultas.
MX2021004682A (es) Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.
PH12017502283A1 (en) A method of treatment
IN2014DN09776A (es)
MX2023003296A (es) Generacion de lineas de cardiomiocitos auriculares y ventriculares a partir de celulas madre pluripotentes humanas.
KR101851270B1 (ko) 자연 살해세포의 대량증식 방법 및 배양용 조성물
MX2023006039A (es) Celulas inmunes defectuosas para suv39h1.
BR112021024822A2 (pt) Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência
Chen et al. Expression and role of Toll-like receptors on human umbilical cord mesenchymal stromal cells
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
WO2018053264A3 (en) Klrg1 depletion therapy
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
MX2020001958A (es) Procedimientos de diagnostico y tratamiento del cancer de pulmon.
IL257929B1 (en) Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy
WO2016201365A3 (en) Methods for treating cancers
MX2018008707A (es) Metodos y composiciones para su uso en la prevencion, tratamiento y/o alivio del cancer.
WO2004011631A3 (en) Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
De Ponte Conti et al. mTOR-dependent translation drives tumor infiltrating CD8+ effector and CD4+ Treg cells expansion
MX2021001252A (es) Partículas de modificación inmunitaria para el tratamiento del cáncer.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
Kwon et al. Regeneration of chronic rotator cuff tear in a rabbit model: synergetic benefits of human umbilical cord blood-derived mesenchymal stem cells, polydeoxyribonucleotides, and microcurrent therapy